9306424 Navia This Phase II Small Business Innovation Research (SBIR) project deals with the development of crosslinked enzyme crystals (CLEC) and their catalytic applications to organic synthesis. Specifically, crystalline esterase and lipase enzymes will be crosslinked with glutaraldehyde to form immobilized enzyme particles which can be lyophilized and stored. These CLECs will remain catalytically active and retain their mechanical integrity under harsh manufacturing conditions. CLEC particles are individual crystals and will not require inert support structures. Their well-defined facets will promote the formation of monodisperse suspensions that will facilitate the scale-up of enzyme-based processes to commercial volumes, particularly in organic solvents. The research will focus on CLECs of lipase and esterase enzymes used by the chemical industry in the manufacture of chiral intermediates and pharmaceuticals. %%% This SBIR Phase II project will continue the advances initially started in the Phase I studies. An important goal of the SBIR Program is the ultimate conversion of NSF-supported research into technological innovation and commercialization. ***

Agency
National Science Foundation (NSF)
Institute
Division of Industrial Innovation and Partnerships (IIP)
Type
Standard Grant (Standard)
Application #
9306424
Program Officer
Darryl G. Gorman
Project Start
Project End
Budget Start
1993-08-01
Budget End
1996-01-31
Support Year
Fiscal Year
1993
Total Cost
$300,000
Indirect Cost
Name
Vertex Pharmaceuticals Incorporated
Department
Type
DUNS #
City
Cambridge
State
MA
Country
United States
Zip Code
02139